We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-4 of 4

IRS extends to June 10 the deadline for submitting error reports on branded prescription drug sales

  • Reed Smith LLP
  • -
  • USA
  • -
  • May 27 2011

On Friday, May 27, 2011, the Internal Revenue Service ("IRS") issued Notice 2011-46 (the "Third Notice"), which extended to June 10, 2011 the deadline to submit error reports in accordance with the dispute resolution process established with respect to the preliminary fee calculation of the 2011 fee imposed on certain manufacturers and importers of branded prescription drugs

IRS issues guidance on calculation of the annual fee imposed on manufacturers and importers of branded prescription drugs under the Affordable Care Act

  • Reed Smith LLP
  • -
  • USA
  • -
  • December 17 2010

On November 29, 2010, the Internal Revenue Service (the "IRS") issued Notice 2010-71, 2010-50 IRB (the "Notice"), which provides guidance on the calculation of the annual fee imposed on certain manufacturers and importers of branded prescription drugs for calendar years beginning after December 31, 2010, pursuant to the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the Affordable Care Act or the "ACA"

IRS extends filing date for reporting 2009 sales of branded prescription drugs under the Affordable Care Act, clarifies information requested from covered entities

  • Reed Smith LLP
  • -
  • USA
  • -
  • January 19 2011

On January 14, 2011, the Internal Revenue Service ("IRS") issued Notice 2011-9 (the "Notice"), which extended the filing date for reporting on Form 8947 a covered entity's 2009 sales of branded prescription drugs under the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the "Affordable Care Act" or the "ACA"

IRS issues guidance on the dispute resolution process for the preliminary fee calculation of the 2011 fee imposed on manufacturers and importers of branded prescription drugs

  • Reed Smith LLP
  • -
  • USA
  • -
  • May 3 2011

On May 2, 2011, the Internal Revenue Service (the "IRS") issued Revenue Procedure 2011-24 (the "Revenue Procedure"), which establishes a dispute resolution process for the preliminary fee calculation for the 2011 fee imposed on certain manufacturers and importers of branded prescription drugs pursuant to the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the "ACA"